IMJUDO Injection 25mg (イジュド点滴静注25mg)

Երկիր: Ճապոնիա

Լեզու: անգլերեն

Աղբյուրը: すりの適正使用協議会 RAD-AR Council, Japan

Ակտիվ բաղադրիչ:

Tremelimumab (Genetical Recombination)

Հասանելի է:

AstraZeneca K.K

INN (Միջազգային անվանումը):

Tremelimumab (Genetical Recombination)

Դեղագործական ձեւ:

injection

Տեղեկատվական թերթիկ

Drug Information Sheet("Kusuri-no-Shiori")
Injection
Published: 03/2023
The information on this sheet is based on approvals granted by the
Japanese regulatory authority. Approval
details may vary by country. Medicines have adverse reactions (risks)
as well as efficacies (benefits). It is
important to minimize adverse reactions and maximize efficacy. To
obtain a better therapeutic response,
patients should understand their medication and cooperate with the
treatment.
BRAND NAME:
IMJUDO INJECTION 25MG
ACTIVE INGREDIENT:
Tremelimumab (Genetical Recombination)
DOSAGE FORM:
injection
IMPRINT OR PRINT ON WRAPPING:
EFFECTS OF THIS MEDICINE
This medicine binds to the T cell (immune cell) receptor (CTLA-4) ,
thereby is considered to
suppress tumor growth by enhancing tumor antigen-specific T cell
proliferation and activation.
It is usually used for for treatment of unresectable
advanced/recurrent non-small-cell lung
cancer, and unresectable hepatocellular carcinoma.
THE FOLLOWING PATIENTS MAY NEED TO BE CAREFUL WHEN USING THIS
MEDICINE.BE SURE TO TELL YOUR DOCTOR
AND PHARMACIST.
・If you have previously experienced any allergic reactions (itch,
rash, etc.) to any medicines
or foods.
If you have or have a history of autoimmune disease or interstitial
lung disease (including
radiation pneumonitis).
・If you are pregnant or breastfeeding.
・If you are taking any other medicinal products. (Some medicines may
interact to enhance or
diminish medicinal effects. Beware of over-the-counter medicines and
dietary supplements
as well as other prescription medicines.)
DOSING SCHEDULE (HOW TO TAKE THIS MEDICINE)
・
Your dosing schedule prescribed by your doctor is((         

to be written by a healthcare
professional
))
・For unresectable advanced/recurrent non-small-cell lung cancer: In
general, for adults,
administer by intravenous infusion over 60 minutes every 3 weeks for
the first 4 doses in
combination with durvalumab (genetical recombination) and
platinum-based chemotherapy,
followed by 7 w